8-K

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM 8-K

CURRENTREPORT

Pursuantto Section 13 or 15(d) of the

SecuritiesExchange Act of 1934

Date of Report (Date of earliest event reported) July 20, 2020

HothTherapeutics, Inc.

(Exact name of registrant as specified in its charter)

1Rockefeller Plaza, Suite 1039

NewYork, New York 10020

(Address of principal executive offices, including ZIP code)

(646)756-2997

(Registrant’s telephone number, including area code)

NotApplicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item8.01 Other Events.

On July 18, 2020, Hoth Therapeutics, Inc. (the “Company”) filed a provisional patent application (the “Patent Application”) with the United States Patent and Trademark Office for the use of one of its current portfolio therapeutics to treat and prevent lung inflammation in patients suffering from a respiratory viral infection, such as that caused by coronoaviruses. The Company has an exclusive license agreement with respect to the use of this drug for other indications.

Coronaviruses (“CoV”) are a large family of viruses that cause illness ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome (SARS-CoV). In 2019, a novel coronavirus named SARS-CoV-2 was identified. Common signs of infection include respiratory symptoms, fever, cough, shortness of breath and breathing difficulties. In more severe cases, infection can cause pneumonia, severe acute respiratory syndrome, acute respiratory distress syndrome, kidney failure and even death. The Patent Application seeks to secure patent protection for the oral and intravenous administrations of the Company’s therapeutic to treat SARS-CoV.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

2